A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)
A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Compensated Cirrhosis Due to Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ENLIGHTEN-Cirrhosis)
The study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]).
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria may apply.
global-roche-genentech-trials@gene.com888-662-6728 (U.S. Only)
Birmingham, Alabama 35205, United States
CABA, C1430CKE, Argentina
Capital Federal, C1280AEB, Argentina
Merkez, Rize Province 53020, Turkey (Türkiye)